Dresden, Germany

Elke Rücker

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Viro Pharmaceuticals Gmbh & Co. Kg. Active years: 2012.



Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Elke Rücker

Introduction

Elke Rücker is a prominent inventor based in Dresden, Germany. She has made significant strides in the field of medical research, particularly in the development of treatments for viral diseases. Her work focuses on enhancing human semen to combat viral infections, showcasing her dedication to improving health outcomes.

Latest Patents

Elke Rücker holds a patent for a groundbreaking invention titled "Human semen enhancer of viral infection peptides (SEVI) and their use." This patent involves peptides that correspond to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also encompasses nucleic acids, antibodies, medicaments, and diagnostics, emphasizing their application in the treatment and diagnosis of viral diseases, especially HIV.

Career Highlights

Throughout her career, Elke Rücker has been associated with Viro Pharmaceuticals GmbH & Co. KG, where she has contributed to innovative research and development. Her expertise in virology and peptide technology has positioned her as a key figure in the fight against viral infections.

Collaborations

Elke has collaborated with notable colleagues, including Knut Adermann and Ludger Ständker. These partnerships have furthered her research and expanded the impact of her inventions in the scientific community.

Conclusion

Elke Rücker's contributions to the field of virology and her innovative patent for enhancing human semen against viral infections highlight her as a leading inventor in medical research. Her work continues to inspire advancements in the treatment of viral diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…